XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of Fair Value Measurement of Financial Assets and Liabilities

The following table presents the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):

 

   As of June 30, 2023 
   Total carrying and estimated fair value   Quoted prices in active markets (Level 1)   Significant other observable inputs (Level 2)   Significant other observable inputs (Level 3) 
Assets:                    
Marketable equity securities  $530   $530   $-   $- 
Total  $530   $530   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities  $29,150   $-   $-   $29,150 
Total  $29,150   $-   $-   $29,150 

 

The following table presents the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):

 

   As of December 31, 2022 
   Total carrying and estimated fair value   Quoted prices in active markets (Level 1)   Significant other observable inputs (Level 2)   Significant other observable inputs (Level 3) 
Assets:                    
Marketable equity securities  $433   $433   $-   $- 
Total  $433   $433   $-   $- 
                     
Liabilities:                    
Contingent consideration liabilities  $45,662   $-   $-   $45,662 
Total  $45,662   $-   $-   $45,662 
Schedule of Cash and Cash Equivalents and Restricted Cash

Schedule of Cash and Cash Equivalents and Restricted Cash

   June 30,   December 31, 
   2023   2022 
Cash and cash equivalents  $17,368   $19,993 
Restricted cash   1,700    1,700 
Cash from discontinuing operations   -    1,510 
Cash, cash equivalents and restricted cash shown in the statements of cash flows  $19,068   $23,203 
Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock

All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock (in thousands):

Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
Numerator:                    
Net loss attributable to Oncocyte Corporation  $(8,333)  $(8,300)  $(5,300)  $(18,591)
Dividend on Series A redeemable convertible preferred stock   (76)   (29)   (166)   (29)
Accretion of Series A redeemable convertible preferred stock   (117)   (43)   (257)   (43)
Deemed dividend on Series A redeemable convertible preferred stock   (118)   -    (118)   - 
Net loss attributable to common stockholders - Basic and Diluted  $(8,644)  $(8,372)  $(5,841)  $(18,663)
                     
Denominator:                    
Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted   8,090    5,652    7,030    5,135 
                     
Basic and diluted net loss per common share  $(1.07)  $(1.48)  $(0.83)  $(3.63)
                     
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:                    
Stock options   483    731    549    657 
RSUs   7    -    10    - 
Warrants   820    845    820    845 
Series A redeemable convertible preferred stock   5    6    5    6 
Total   1,315    1,582    1,384    1,508